Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Completed · Phase 2
Conditions studied: Carcinoma, Non-Small-Cell Lung
In brief
Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor (EGFR wt) (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK)-negative rearrangement, and mesenchymal epithelial transition (MET) mutations leading to exon 14 deletion (referred to as MET mutation hereafter) and/or MET amplification.
Key facts
- Study ID
- NCT02414139
- Run by
- Novartis Pharmaceuticals
- People needed
- 373
- Starts
- 2015-06-11
- Expected to finish
- 2023-05-16
- Last updated by the study team
- 2024-03-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University Of California Los Angeles Dept of Onc — Los Angeles, California, United States
- University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center — Orange, California, United States
- H Lee Moffitt Cancer Center and Research Institute . — Tampa, Florida, United States
- University of Iowa Hospitals and Clinics SC-3 — Iowa City, Iowa, United States
- Massachusetts General Hospital MGH Cancer Center — Boston, Massachusetts, United States
- VA Ann Arbor Health System VA Ann Arbor Health System — Ann Arbor, Michigan, United States
- Mayo Clinic Rochester . — Rochester, Minnesota, United States
- Oregon Health and Science University SC — Portland, Oregon, United States
- Lehigh Valley Health Network SC — Allentown, Pennsylvania, United States
- Andrew and Patel Associates — Camp Hill, Pennsylvania, United States
- Mays Cancer Ctr Uthsa Mdacc SC-5 — San Antonio, Texas, United States
- University of Utah / Huntsman Cancer Institute Oncology — Salt Lake City, Utah, United States
- Novartis Investigative Site — CABA, Buenos Aires, Argentina
- Novartis Investigative Site — Buenos Aires, Buenos Aires F.D., Argentina
- Novartis Investigative Site — La Rioja, Argentina
- Novartis Investigative Site — Vienna, Austria
- Novartis Investigative Site — Leuven, Belgium
- Novartis Investigative Site — Marseille, Bouches Du Rhone, France
- Novartis Investigative Site — Dijon, Cote D Or, France
- Novartis Investigative Site — Clermont-Ferrand, France
- Novartis Investigative Site — La Tronche, France
- Novartis Investigative Site — Lille, France
- Novartis Investigative Site — Marseille, France
- Novartis Investigative Site — Paris, France
- Pacific Shores Medical Group SC — Long Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.